Researchers have uncovered changes in the cellular response throughout lung damage caused by SARS-CoV-2—the virus behind ...

Using a newly developed mouse model, researchers found that exposure to the SARS-CoV-2 spike protein alone was enough to induce COVID-19-like symptoms including severe inflammation in the lungs.

Researchers at Umeå University have discovered that the SARS-CoV-2 variant omicron has developed a stronger binding to human lung cells through optimized interaction with heparan sulfate, a sugar ...

A healthy person will show no signs of lung inflammation, therefore no yellow areas. That’s where the body is trying to block the infection. As the video shows, the SARS-CoV-2 virus goes ...

WEHI scientists discovered a drug that blocks long COVID in mice and may improve acute treatment options beyond current antivirals like Paxlovid. WEHI researchers have developed a drug compound that ...

the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells in the lungs remain elusive. Here we conducted integrated single-cell profiling of SARS-CoV-2 ...

A SARS-CoV-2 particle enters a person's nose or mouth and floats in the airway until it brushes against a lung cell that has an ACE2 receptor on the surface. The virus binds to that cell ...

Researchers develop quinoline-based drug with inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro).

Tucked away on Mount Desert Island off the coast of Maine, the Jackson Laboratory (JAX) may seem removed from the pandemic ...

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical ...

Now, SARS-CoV-2 circulates along with other common ... People over 65 Those with a weakened immune system Those with heart or lung diseases RSV doesn't usually come with long-term symptoms.